
TY  - JOUR
AU  - Richardson, Paul G.
AU  - Mitsiades, Constantine S.
AU  - Laubach, Jacob P.
AU  - Lonial, Sagar
AU  - Chanan-Khan, Asher A.
AU  - Anderson, Kenneth C.
TI  - Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers
JO  - British Journal of Haematology
VL  - 152
IS  - 4
SN  - 0007-1048
UR  - https://doi.org/10.1111/j.1365-2141.2010.08360.x
DO  - doi:10.1111/j.1365-2141.2010.08360.x
SP  - 367
EP  - 379
KW  - cancer
KW  - heat shock protein 90
KW  - myeloma
KW  - peripheral neuropathy
KW  - tanespimycin
PY  - 2011
AB  - Summary Heat shock protein 90 (HSP90) is a molecular chaperone that is induced in response to cellular stress and stabilizes client proteins involved in cell cycle control and proliferative/anti-apoptotic signalling. HSP90 is overexpressed in a range of cancers, and may contribute to tumour cell survival by stabilizing aberrant signalling proteins and by interfering with apoptosis. Tanespimycin, an HSP90 inhibitor, reduces tumour cell survival in vitro. In multiple myeloma (MM), HSP90 inhibition affects multiple client proteins that contribute to tumour cell survival, including the IGF1 receptor and the IL-6 receptor, and elements of the PI3/Akt, STAT3, and MAPK signalling pathways. HSP90 inhibition also abrogates the protective effect of bone marrow stromal cells and inhibits angiogenesis and osteoclastogenesis. Tanespimycin acts synergistically with the proteasome inhibitor bortezomib in MM cells and tumour explants, possibly reducing their ability to resist bortezomib-induced stress to the endoplasmic reticulum. The combination of tanespimycin and bortezomib has demonstrated significant and durable responses with acceptable toxicity in a phase I/II study in patients with relapsed and relapsed/refractory MM. HSP90 inhibition is a promising strategy in MM especially in combination with bortezomib; additional studies will further evaluate optimal dosings of candidate drugs and schedules, as well as confirm efficacy in comparative phase III trials.
ER  - 

TY  - JOUR
TI  - Subspecialty Poster Sessions
JO  - European Journal of Clinical Investigation
JA  - Eur J Clin Invest
VL  - 45
IS  - s2
SN  - 0014-2972
UR  - https://doi.org/10.1111/eci.12436
DO  - doi:10.1111/eci.12436
SP  - 69
EP  - 92
PY  - 2015
ER  - 

TY  - JOUR
TI  - P941 - P1197
JO  - Clinical Microbiology and Infection
VL  - 12
IS  - s4
SN  - 1198-743X
UR  - https://doi.org/10.1111/j.1470-9465.2006.12_4_1429.x
DO  - doi:10.1111/j.1470-9465.2006.12_4_1429.x
PY  - 2006
ER  - 

TY  - JOUR
TI  - Plenary Sessions
JO  - Basic & Clinical Pharmacology & Toxicology
JA  - Basic Clin Pharmacol Toxicol
VL  - 125
IS  - S4
SN  - 1742-7835
UR  - https://doi.org/10.1111/bcpt.13301
DO  - doi:10.1111/bcpt.13301
SP  - 4
EP  - 55
PY  - 2019
ER  - 

TY  - JOUR
AU  - Pillai, Jagan A.
AU  - Maxwell, Sean
AU  - Bena, James
AU  - Bekris, Lynn M.
AU  - Rao, Stephen M.
AU  - Chance, Mark
AU  - Lamb, Bruce T.
AU  - Leverenz, James B.
AU  - for the Alzheimer’s Disease Neuroimaging Initiative
TI  - Key inflammatory pathway activations in the MCI stage of Alzheimer’s disease
JO  - Annals of Clinical and Translational Neurology
JA  - Ann Clin Transl Neurol
VL  - 6
IS  - 7
SN  - 2328-9503
UR  - https://doi.org/10.1002/acn3.50827
DO  - doi:10.1002/acn3.50827
SP  - 1248
EP  - 1262
PY  - 2019
AB  - Abstract Objective To determine the key inflammatory pathways that are activated in the peripheral and CNS compartments at the mild cognitive impairment (MCI) stage of Alzheimer?s disease (AD). Methods A cross-sectional study of patients with clinical and biomarker characteristics consistent with MCI-AD in a discovery cohort, with replication in the Alzheimer?s Disease Neuroimaging Initiative (ADNI) cohort. Inflammatory analytes were measured in the CSF and plasma with the same validated multiplex analyte platform in both cohorts and correlated with AD biomarkers (CSF A?42, total tau (t-tau), phosphorylated tau (p-tau) to identify key inflammatory pathway activations. The pathways were additionally validated by evaluating genes related to all analytes in coexpression networks of brain tissue transcriptome from an autopsy confirmed AD cohort to interrogate if the same pathway activations were conserved in the brain tissue gene modules. Results Analytes of the tumor necrosis factor (TNF) signaling pathway (KEGG ID:4668) in the CSF and plasma best correlated with CSF t-tau and p-tau levels, and analytes of the complement and coagulation pathway (KEGG ID:4610) best correlated with CSF A?42 levels. The top inflammatory signaling pathways of significance were conserved in the peripheral and the CNS compartments. They were also confirmed to be enriched in AD brain transcriptome gene clusters. Interpretation A cell-protective rather than a proinflammatory analyte profile predominates in the CSF in relation to neurodegeneration markers among MCI-AD patients. Analytes from the TNF signaling and the complement and coagulation pathways are relevant in evaluating disease severity at the MCI stage of AD.
ER  - 

TY  - JOUR
AU  - Czarzasta, Joanna
AU  - Habich, Aleksandra
AU  - Siwek, Tomasz
AU  - Czapliński, Adam
AU  - Maksymowicz, Wojciech
AU  - Wojtkiewicz, Joanna
TI  - Stem cells for ALS: An overview of possible therapeutic approaches
JO  - International Journal of Developmental Neuroscience
JA  - International Journal of Developmental Neuroscience
VL  - 57
IS  - C
SN  - 0736-5748
UR  - https://doi.org/10.1016/j.ijdevneu.2017.01.003
DO  - doi:10.1016/j.ijdevneu.2017.01.003
SP  - 46
EP  - 55
KW  - Amyotrophic lateral sclerosis
KW  - Risk factors
KW  - Stem cells therapy
PY  - 2017
AB  - Abstract Amyotrophic lateral sclerosis (ALS) is an unusual, fatal, neurodegenerative disorder leading to the loss of motor neurons. After diagnosis, the average lifespan ranges from 3 to 5 years, and death usually results from respiratory failure. Although the pathogenesis of ALS remains unclear, multiple factors are thought to contribute to the progression of ALS, such as network interactions between genes, environmental exposure, impaired molecular pathways and many others. The neuroprotective properties of neural stem cells (NSCs) and the paracrine signaling of mesenchymal stem cells (MSCs) have been examined in multiple pre-clinical trials of ALS with promising results. The data from these initial trials indicate a reduction in the rate of disease progression. The mechanism through which stem cells achieve this reduction is of major interest. Here, we review the to-date pre-clinical and clinical therapeutic approaches employing stem cells, and discuss the most promising ones.
ER  - 

TY  - JOUR
TI  - ASBMR/ISCD Joint Symposium on Bone Densitometry Y2K to Y3K
JO  - Journal of Bone and Mineral Research
VL  - 14
IS  - S1
SN  - 0884-0431
UR  - https://doi.org/10.1111/jbmr.1999.14.s1.1
DO  - doi:10.1111/jbmr.1999.14.s1.1
SP  - 1
EP  - 1919
PY  - 1999
ER  - 

TY  - JOUR
TI  - British Society for Matrix Biology Meeting, Autumn 2006
JO  - International Journal of Experimental Pathology
VL  - 88
IS  - 4
SN  - 0959-9673
UR  - https://doi.org/10.1111/j.1365-2613.2007.00525.x
DO  - doi:10.1111/j.1365-2613.2007.00525.x
SP  - A46
EP  - A74
PY  - 2007
ER  - 

TY  - JOUR
AU  - Slutsky, Arthur S.
AU  - Silliman, Christopher C.
AU  - Brand, Anneke
AU  - Wallis, Jonathan P.
TI  - ARDS-TRALI
JO  - Transfusion Alternatives in Transfusion Medicine
VL  - 6
IS  - s1
SN  - 1295-9022
UR  - https://doi.org/10.1111/j.1778-428X.2004.tb00143.x
DO  - doi:10.1111/j.1778-428X.2004.tb00143.x
SP  - 45
EP  - 50
PY  - 2004
ER  - 

TY  - JOUR
AU  - Bull, Sarah
AU  - Burnett, Karin
AU  - Vassaux, Kate
AU  - Ashdown, Lini
AU  - Brown, Terry
AU  - Rushton, Lesley
C7  - 572E
TI  - Extensive literature search and provision of summaries of studies related to the oral toxicity of perfluoroalkylated substances (PFASs), their precursors and potential replacements in experimental animals and humans. Area 1: Data on toxicokinetics (absorption, distribution, metabolism, excretion) in in vitro studies, experimental animals and humans. Area 2: Data on toxicity in experimental animals. Area 3: Data on observations in humans
JO  - EFSA Supporting Publications
JA  - EFSA Supporting Publications
VL  - 11
IS  - 4
SN  - 2397-8325
UR  - https://doi.org/10.2903/sp.efsa.2014.EN-572
DO  - doi:10.2903/sp.efsa.2014.EN-572
SP  - 572E
KW  - perfluoroalkylated substances
KW  - toxicity
KW  - in vitro
KW  - experimental animals
KW  - humans
KW  - literature search
PY  - 2014
ER  - 

C7  - pp. 339-347
TI  - Index
SN  - 9780470060957
UR  - https://doi.org/10.1002/9780470988176.index
DO  - doi:10.1002/9780470988176.index
SP  - 339-347
PY  - 2014
ER  - 

TY  - JOUR
TI  - Subspecialty Poster Sessions
JO  - European Journal of Clinical Investigation
VL  - 41
IS  - s1
SN  - 9780470060957
UR  - https://doi.org/10.1111/j.1365-2362.2011.02507.x
DO  - doi:10.1111/j.1365-2362.2011.02507.x
SP  - 3
EP  - 22
PY  - 2011
ER  - 

TY  - JOUR
TI  - Abstracts for Poster Presentation
JO  - Journal of Gastroenterology and Hepatology
VL  - 22
IS  - s2
SN  - 9780470060957
UR  - https://doi.org/10.1111/j.1440-1746.2007.05194.x
DO  - doi:10.1111/j.1440-1746.2007.05194.x
SP  - A190
EP  - A219
PY  - 2007
ER  - 

TY  - JOUR
AU  - Tay, Chor Yong
AU  - Fang, Wanru
AU  - Setyawati, Magdiel Inggrid
AU  - Sum, Chee Peng
AU  - Xie, Jianping
AU  - Ng, Kee Woei
AU  - Chen, Xiaodong
AU  - Hong, Catherine Hsu Ling
AU  - Leong, David Tai
TI  - Reciprocal Response of Human Oral Epithelial Cells to Internalized Silica Nanoparticles
JO  - Particle & Particle Systems Characterization
JA  - Part. Part. Syst. Charact.
VL  - 30
IS  - 9
SN  - 9780470060957
UR  - https://doi.org/10.1002/ppsc.201300111
DO  - doi:10.1002/ppsc.201300111
SP  - 784
EP  - 793
KW  - human buccal epithelium
KW  - inflammation
KW  - nanomaterials
KW  - reactive oxygen species
KW  - silica nanoparticles
PY  - 2013
AB  - Silica nanoparticles (SiO2 NPs) are one of the most widely used engineered nanoparticles and can been found in a wide range of consumer products. Despite their massive global production scale, little is known about their potential effects in the context of unintended exposure or ingestion. Using TR146 cells as an in vitro model of the human oral buccal mucosa, the uptake, spatial intracellular distribution, reactive oxygen species (ROS) production, inflammatory response, and cytotoxic effects of commercial SiO2 NPs are examined. SiO2 NPs are shown to dock and cross the cellular membrane barrier in a dose?time-dependent manner. Confocal sectioning reveals translocation of SiO2 NPs into the cell nucleus after 12 h of exposure. A concentration threshold of more than 500 ? 10?6 m is observed, above which SiO2 NPs are shown to exert significant oxidative stress with concomitant upregulation of inflammatory genes IL6 and TNFA. Further analysis of the p53 pathway and a series of apoptotic and cell cycle biomarkers reveals intracellular accumulation of SiO2 NPs exert marginal nanotoxicity. Collectively, this study provides important information regarding the uptake, intracellular distribution, and potential adverse cellular effects of SiO2 NPs commonly found in consumer products in the human oral epithelium.
ER  - 

TY  - JOUR
TI  - Abstracts of oral/poster sessions
JO  - Pediatric Pulmonology
JA  - Pediatr. Pulmonol.
VL  - 32
IS  - S23
SN  - 9780470060957
UR  - https://doi.org/10.1002/ppul.1950322367
DO  - doi:10.1002/ppul.1950322367
SP  - 170
EP  - 199
PY  - 2001
ER  - 

TY  - JOUR
TI  - ESSR ABSTRACTS 2010
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 97
IS  - S4
SN  - 9780470060957
UR  - https://doi.org/10.1002/bjs.7158
DO  - doi:10.1002/bjs.7158
SP  - S1
EP  - S58
PY  - 2010
AB  - Abstract The 45th Congress of the European Society for Surgical Research takes place this year in Geneva, Switzerland, 9?12 June 2010, under the presidency of Mustafa Cikirikcioglu, MD, PhD. Copyright ? 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
ER  - 

TY  - JOUR
TI  - Abstract
JO  - Journal of Thrombosis and Haemostasis
JA  - Journal of Thrombosis and Haemostasis
VL  - 5
IS  - S2
SN  - 9780470060957
UR  - https://doi.org/10.1111/j.1538-7836.2007.tb00011.x
DO  - doi:10.1111/j.1538-7836.2007.tb00011.x
SP  - P-S-407
EP  - P-S-599
PY  - 2007
ER  - 

TY  - JOUR
TI  - Published Only
JO  - Journal of Digestive Diseases
JA  - Journal of Digestive Diseases
VL  - 16
IS  - S1
SN  - 9780470060957
UR  - https://doi.org/10.1111/1751-2980.12277
DO  - doi:10.1111/1751-2980.12277
SP  - 29
EP  - 146
PY  - 2015
ER  - 

TY  - JOUR
TI  - ANZSBT oral abstracts presented at the HSANZ/ANZSBT/ASTH with APSTH Annual Scientific Meeting, Melbourne, 28–31 October 2012
JO  - Transfusion Medicine
JA  - Transfusion Med
VL  - 23
IS  - 4
SN  - 9780470060957
UR  - https://doi.org/10.1111/tme.12055
DO  - doi:10.1111/tme.12055
SP  - 287
EP  - 298
PY  - 2013
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - International Journal of Rheumatic Diseases
JA  - Int J Rheum Dis
VL  - 17
IS  - s1
SN  - 9780470060957
UR  - https://doi.org/10.1111/1756-185x.12344
DO  - doi:10.1111/1756-185x.12344
SP  - 1
EP  - 133
PY  - 2014
ER  - 
